📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
48 articles scientifiques publiés — un praticien à la pointe de la recherche
Référence presse grand public
Cité 10 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
32
32 articles ont été cités au moins 32fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
h-index
Total citations reçues
4 362
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
255
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
73
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre Jean Bernard · Clinique Victor Hugo
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial
2025ArticleThe Lancet
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial
2024ArticleJournal of Clinical Oncology
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
2023ArticleInternational Journal of Gynecological Cancer
Audit croisé des activités de pharmacie clinique entre deux centres hospitalo-universitaires : retour d’expérience d’une démarche stimulante
2023ArticleLe Pharmacien Clinicien
The place of the relative at the time of the announcement of cancer progression
2023ArticlePalliative and Supportive Care
Physical Activity Program for the Survival of Elderly Patients With Lymphoma: Study Protocol for Randomized Phase 3 Trial
2022ArticleJMIR Research Protocols
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study
2022ArticleGynecologic Oncology
Neuromuscular, Psychological, and Sleep Predictors of Cancer-Related Fatigue in Cancer Patients
2021ArticleClinical Breast Cancer
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 - Le Mans.maville.com · 27/02/2026
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxOR1RId09DdE5HUzh3VmQ0dUUxWlJnengweFhIRFVTRFdUQUFwVFJOMlhiOWMzQ0Exd3V4WkJDeGZhMi05aDE1Nk00ZHRuR1FuVlk0R0otT283bE9jVVZ0Nmxxd3JWaFdwcnZpOVR6aGY0eUxibW5tdVRCSVZndVM3bUtGU3V1Y3o2M2h3VWZ4Y1lIOG5zX01MOVEwallVTGl5SVlrRWpnNDdKWWYyV2ZoektlWHFueGlvR1
📰 La Montagne · 31/08/2023
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPaFdOalBhRFBVcG41SUZoeWlDY3c3Njl3OTNjSktFYk5HRTA1WDdTYUpoZ2x3WEhBNFViRXIxWmdsOXFWcWpJSGhwdjdiaUpwNjhuekI1alZrYXR4VmxlLW5BSmZNaktUUkRhcGZreEdkN015ei1nX2VfUV8xaU9ubFc5R2J0Uzc1UzY5aVpMM1ctVlhYVmtLUTV5ZEs0UW5laUV0emVzQjBhSDJ1cDd4Z1VwMEZoaG0wTz
📰 Ouest-France · 27/10/2022
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxQNkdQTFZsNjZPMm00blFYRDZ2alRKZkdfa2Q5WVZTZktQMUNsRlJuRmluWWxmUExjYWEyS05wQXdsOG5Pa1RFWmVaTUtFRXhqWWV0LWNTR0Z6TzItNUtISUVkbG9CelJkblVpc3ZySlJxVUQ3dThHWVEyWWVJZDhPaFBPdE1DdjROZlJJRVp4WmdkV0ZOdzFqaHVRVWtuVWFMbjFRTHAyNFB4WUk4WlYyVG5WRlFZOHp2R2
📰 ici.fr · 30/09/2021
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNb1BsSVhkdFhzMDRJaXUxRkQ0TEI4RVQ1akhMUVFjNC1uQ1UxT3FRLTB3aFJhazB2RWpUTzNsUWx6UjByaEdRa2NQR3VmdFNTeU83SVlHbEItS2NNZ0lpTzI3Z3BpMWpyRHpVR29ZLWdyeHhHTm54QW4tVVJwQXdtNWVuVFhJR0dsVTJCZllMVzZUNVZPaWVZSmEzczY4Y1dxQkxHZEhQMmRDcUVTWGVv?oc=5" target=
📰 Ouest-France · 23/09/2021
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxNRWluSXJmT1lyUHRnQ3UyTmxHa1VxTTBoSkphRkc2b1MzNkFsVTZPU2RsN2tyWlFPU1ZVTHYxdElfQjJucEg2MVNKRG95SFpiN2ZCcF9zSk45ejdCSFVlb2xzSGJvQnM4bDJoR2Rhb3FteG1kdElqTTRqekM5M0NFUS1oZ2RVM1BPZWdlVjRYNzhBQk5mako4VHZZTGFrNGNyWkhiOGhqbGFNazNsT2NJX0JOakxaS1A3dm
📰 Actu.fr · 07/06/2020
<a href="https://news.google.com/rss/articles/CBMikAJBVV95cUxNM2poMFFkbnpkQVF3VkgxaFByM0Yzc3Vyb2REM283UlBIVVdLT2o2b055djB0UFhZT0ZHRkliZFBYT09BY3RTVVJ3TmxCalZjVEt0UFRTNk5nZW55UW1MWngybmRNaml5V2w4OVRTQ2FWdVNaRFJHREtkSWQ5TG1IX29faktXZnRwc1QyaGU5X2pZbkMyOE9IUEJNMnBFQUU2RV80MWF5SThaN2ZSdGtoNkstNzBfaUNjSn
📰 Ouest-France · 21/02/2020
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPVk93ZjFDQ2RJX1pqaFZnamtnN1dDS1k4aEZZc2FnWndaakpoNVJCczFRZmhPMjRKX2dJVDk5OTByU184N1l5eVdMRWtRUlRpcVR5bGpCZ0g4U0Nrc0hNUVZhUDIzejdQZkFlTU1HbDR4c1lSWXA5azhFa1lZODdUN0o5LXpmRjFiOXhMOGdEaTZKQ2ZneENod0o5OVZ5ZHhZTGF6S1gtdDBjMTBfdnlHQ2dzUURzUm9sbX
📰 Ouest-France · 21/02/2020
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOQWF2SEU2VkRScno5TElRbVlVV1NVV2VnMUpVZ1A5MEEzUG4yQ0k5Z09Da1pwR1ZWbmE0a194YV94M082R2pscWxndkN4aEQ2dmdvclZ1WHRmeFJMbFVRSnd6MWdJdVdmMExkTVVIblI0ZEE0TWw5ckQ4QlRqaGNZc3dkT3BvRjJjcWxleTE4V0EyaG93MmFXSklyMGJYUzJfM0x3elNwNDdOT2VvaVdRRkxBMnhid1hDRE
📰 Ouest-France · 15/11/2019
<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxPRy13UHZ2Yng3STZMYXFUZkl3dGQ1bGE4WlFrUnpvUFhtYm5KNGRkQ3hMMkdqSFA1eGliYTIydVVFYjZXV0I1Vk15aTBXOWhqa0w0Z3BuWTVaX2E4d0xMZWdtaDVzOHBFTDdUY1JhMU1rdWlQc1ZxNmdFWlZLUkY2bjl4aXB2NVQ1VDVXZW95UDlITU9acTl0NEtqUEh0REdPSXhvdjV0WEdUZXUyeUJYUWNtUmtsRDB2dU
📰 Ouest-France · 04/04/2017
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPMW1sOHNKVmlMTm1RNWVBbjhiRWExcUJBcm1ENGc2T0NJUkQtY2I3QXVnTWpGMjkzQlg2TnJkQmRaY0ZjUUNIb09pZFZiazl0M2RNRW5ZeEZWY1Z0R05qck1IWjlnejN4S0VQV2tORTh3R0VCTVh2N3duTjNEU1pyMUhkZzBKaDdlTXhNUGl3OEpibXNkRVJ2SGZKend0LTA1U1ROcFVqU2ZRUHU2ei15bGdyQ1pFU0Q3eH
Journal of the National Cancer Institute · 2017
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009
Purpose To evaluate the efficacy of trastuzumab in patients with node-positive breast cancer treated with surgery, adjuvant chemotherapy, radiotherapy, and hormone therapy if applicable. Patients and Methods Three thousand ten patients with operable node-positive breast cancer were randomly assigned to receive adjuvant anthracycline-based chemotherapy with or without docetaxel. Patients who presented human epidermal growth factor receptor 2 (HER2) -overexpressing tumors were secondary randomly assigned to either a sequential regimen of trastuzumab (6 mg/kg every 3 weeks) for 1 year or observation. The primary end point was disease-free survival (DFS). Results Overall 528 patients were randomly assigned between trastuzumab (n = 260) and observation (n = 268) arm. Of the 234 patients (90%) who received at least one administration of trastuzumab, 196 (84%) received at least 6 months of treatment, and 41 (18%) discontinued treatment due to cardiac events (any grade). At the date of analysis (October 2007), 129 DFS events were recorded. Random assignment to the trastuzumab arm was associated with a nonsignificant 14% reduction in the risk of relapse (hazard ratio, 0.86; 95% CI, 0.61 to 1.22; P = .41, log-rank stratified on pathologic node involvement). Three-year DFS rates were 78% (95% CI, 72.3 to 82.5) and 81% (95% CI, 75.3 to 85.4) in the observation and trastuzumab arms, respectively. Conclusion After a 47-month median follow-up, 1 year of trastuzumab given sequentially after adjuvant chemotherapy was not associated with a statistically significant decrease in the risk of relapse.
Journal of the National Cancer Institute · 2006
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Clinical cancer research : an official journal of the American Association for Cancer Research · 2025 · Clinical Trial, Phase III
Sandoval JL, Kiavue N, Djerroudi L, Jacot W, et al.
Palliative & supportive care · 2024 · Journal Article
Ingrand I, Laurent E, Lecomte T, Cojocarasu O, et al.
The oncologist · 2021 · Clinical Trial, Phase IV
Pignata S, Scambia G, Villanucci A, Naglieri E, et al.
The oncologist · 2021 · Journal Article
Zelek L, Debourdeau P, Bourgeois H, Wagner JP, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2021 · Journal Article
Lim B, Potter DA, Salkeni MA, Silverman P, et al.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2021 · Journal Article
Gac MM, Loaec C, Silve J, Vaucel E, et al.
Breast cancer research : BCR · 2019 · Clinical Trial, Phase II
Jacot W, Cottu P, Berger F, Dubot C, et al.
Bulletin du cancer · 2019 · Journal Article
Grudé F, Marhuenda F, Déniel-Lagadec D, Bessard R, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019 · Journal Article
Denis F, Voog E, Pointreau Y, Bourgeois H, et al.
Breast (Edinburgh, Scotland) · 2019 · Journal Article
Curtit E, Vannetzel JM, Darmon JC, Roche S, et al.
Journal for immunotherapy of cancer · 2019 · Clinical Trial, Phase I
Keilholz U, Mehnert JM, Bauer S, Bourgeois H, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018 · Journal Article
Voog E, Campion L, du Rusquec P, Bourgeois H, et al.
Breast cancer research : BCR · 2017 · Journal Article
Curtit E, Pivot X, Henriques J, Paget-Bailly S, et al.
European journal of cancer (Oxford, England : 1990) · 2017 · Clinical Trial, Phase III
Pivot X, Fumoleau P, Pierga JY, Delaloge S, et al.
NPJ breast cancer · 2017 · Journal Article
Pivot X, Romieu G, Fumoleau P, Rios M, et al.
Bulletin du cancer · 2016 · Journal Article
Delaloge S, Bachelot T, Bidard FC, Espie M, et al.
Bulletin du cancer · 2016 · Journal Article
Delaloge S, Bachelot T, Bidard FC, Espie M, et al.
Simulation in healthcare : journal of the Society for Simulation in Healthcare · 2016 · Letter
Hureaux J, Cartier-Chatron I, Bourgeois H, Rolland-Lozachmer G, et al.
Bulletin du cancer · 2013 · English Abstract
Grudé F, Bessard R, Bourgeois H, Douillard JY, et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2012 · Clinical Trial, Phase II
Lheureux S, Krieger S, Weber B, Pautier P, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009 · Journal Article
Spielmann M, Roché H, Delozier T, Canon JL, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene · 2008 · Journal Article
Pihet M, Bourgeois H, Mazière JY, Berlioz-Arthaud A, et al.
American journal of clinical oncology · 2006 · Clinical Trial, Phase I
Bourgeois H, Joly F, Pujade-Lauraine E, Cure H, et al.
American journal of clinical oncology · 2006 · Clinical Trial, Phase I
Bourgeois H, Ferru A, Lortholary A, Delozier T, et al.
American journal of clinical oncology · 2004 · Clinical Trial
Bourgeois H, Billiart I, Chabrun V, Chieze S, et al.
Breast (Edinburgh, Scotland) · 2024 · Randomized Controlled Trial
Freyer G, Martinez-Jañez N, Kukielka-Budny B, Ulanska M, et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024 · Clinical Trial, Phase III
Lorusso D, Mouret-Reynier MA, Harter P, Cropet C, et al.
JMIR research protocols · 2022 · Journal Article
Dubu J, Boyas S, Roland V, Landry S, et al.
Oncology · 2018 · Journal Article
Landry S, Chasles G, Pointreau Y, Bourgeois H, et al.
JMIR research protocols · 2022 · Journal Article
Dubu J, Boyas S, Roland V, Landry S, et al.
Clinical breast cancer · 2013 · Clinical Trial, Phase III
Pritchard KI, Burris HA 3rd, Ito Y, Rugo HS, et al.
Breast (Edinburgh, Scotland) · 2018 · Journal Article
Janni W, Chan A, Nusch A, Alba E, et al.
Clinical breast cancer · 2013 · Clinical Trial, Phase III
Pritchard KI, Burris HA 3rd, Ito Y, Rugo HS, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019 · Journal Article
Blouet A, Zinger M, Capitain O, Landry S, et al.
Oncology · 2018 · Journal Article
Landry S, Chasles G, Pointreau Y, Bourgeois H, et al.
Oncotarget · 2016 · Journal Article
Cox DG, Curtit E, Romieu G, Fumoleau P, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2012 · Clinical Trial, Phase III
Martin M, Bell R, Bourgeois H, Brufsky A, et al.
Clinical breast cancer · 2021 · Journal Article
Chartogne M, Rahmani A, Landry S, Bourgeois H, et al.
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
Abstract Background In this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC. Methods Main inclusion cri
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
Abstract Background Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combi
Additional file 1: of Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
Table S1. List of 94 variants associated with risk, involved in the 94-SNP risk score (identification and characteristics of variants). (XLS 41 kb)
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · Randomized Controlled Trial
Bidard FC, Kiavue N, Jacot W, Bachelot T, et al.
Journal of medical Internet research · 2023 · Randomized Controlled Trial
Le Du K, Septans AL, Maloisel F, Vanquaethem H, et al.
JMIR research protocols · 2022 · Journal Article
Dubu J, Boyas S, Roland V, Landry S, et al.
Gynecologic oncology · 2022 · Clinical Trial, Phase II
Joly F, Fabbro M, Berton D, Lequesne J, et al.
British journal of cancer · 2021 · Journal Article
Cabel L, Berger F, Cottu P, Loirat D, et al.
JAMA oncology · 2021 · Journal Article
Bidard FC, Jacot W, Kiavue N, Dureau S, et al.
Journal of the National Cancer Institute · 2017 · Clinical Trial, Phase III
Denis F, Lethrosne C, Pourel N, Molinier O, et al.
The Lancet. Oncology · 2013 · Clinical Trial, Phase II
Robertson JF, Ferrero JM, Bourgeois H, Kennecke H, et al.
Breast cancer research and treatment · 2012 · Clinical Trial, Phase II
Lortholary A, Hardy-Bessard AC, Bachelot T, de Rauglaudre G, et al.
Gynecologic oncology · 2010 · Clinical Trial, Phase II
Joly F, Sevin E, Lortholary A, Priou F, et al.
Anticancer research · 2009 · Clinical Trial, Phase II
Weber B, Lortholary A, Mayer F, Bourgeois H, et al.
Anticancer research · 2007 · Clinical Trial, Phase II
Tubiana-Hulin M, Becette V, Bieche I, Mauriac L, et al.
Journal of the National Cancer Institute · 2006 · Clinical Trial, Phase III
Pfisterer J, Weber B, Reuss A, Kimmig R, et al.
American journal of clinical oncology · 2006 · Clinical Trial, Phase II
Planchard D, Bourgeois H, Adoun M, Paitel JF, et al.
✨ Profil synthétique
IA · 20/05/2026Le Dr Hugues Bourgeois est un rhumatologue avec une production scientifique importante, comme en témoignent ses 255 publications et son h-index de 32. Ses recherches portent principalement sur le cancer, notamment le cancer de l'ovaire et du sein, ainsi que sur les traitements et les thérapies ciblées. Ses publications sur PubMed couvrent également des sujets tels que l'activité physique, la gériatrie et la pharmacovigilance.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.